Literature DB >> 29492746

Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards.

Iván Díaz1, Elizabeth Colantuoni2, Daniel F Hanley3, Michael Rosenblum2.   

Abstract

We present a new estimator of the restricted mean survival time in randomized trials where there is right censoring that may depend on treatment and baseline variables. The proposed estimator leverages prognostic baseline variables to obtain equal or better asymptotic precision compared to traditional estimators. Under regularity conditions and random censoring within strata of treatment and baseline variables, the proposed estimator has the following features: (i) it is interpretable under violations of the proportional hazards assumption; (ii) it is consistent and at least as precise as the Kaplan-Meier and inverse probability weighted estimators, under identifiability conditions; (iii) it remains consistent under violations of independent censoring (unlike the Kaplan-Meier estimator) when either the censoring or survival distributions, conditional on covariates, are estimated consistently; and (iv) it achieves the nonparametric efficiency bound when both of these distributions are consistently estimated. We illustrate the performance of our method using simulations based on resampling data from a completed, phase 3 randomized clinical trial of a new surgical treatment for stroke; the proposed estimator achieves a 12% gain in relative efficiency compared to the Kaplan-Meier estimator. The proposed estimator has potential advantages over existing approaches for randomized trials with time-to-event outcomes, since existing methods either rely on model assumptions that are untenable in many applications, or lack some of the efficiency and consistency properties (i)-(iv). We focus on estimation of the restricted mean survival time, but our methods may be adapted to estimate any treatment effect measure defined as a smooth contrast between the survival curves for each study arm. We provide R code to implement the estimator.

Entities:  

Keywords:  Covariate adjustment; Efficiency; Random censoring; Targeted minimum loss based estimation

Year:  2018        PMID: 29492746     DOI: 10.1007/s10985-018-9428-5

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  27 in total

1.  Causal inference on the difference of the restricted mean lifetime between two groups.

Authors:  P Y Chen; A A Tsiatis
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data.

Authors:  Jun Xie; Chaofeng Liu
Journal:  Stat Med       Date:  2005-10-30       Impact factor: 2.373

3.  Doubly robust estimation in missing data and causal inference models.

Authors:  Heejung Bang; James M Robins
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

4.  Super learner.

Authors:  Mark J van der Laan; Eric C Polley; Alan E Hubbard
Journal:  Stat Appl Genet Mol Biol       Date:  2007-09-16

5.  Improved double-robust estimation in missing data and causal inference models.

Authors:  Andrea Rotnitzky; Quanhong Lei; Mariela Sued; James M Robins
Journal:  Biometrika       Date:  2012-04-29       Impact factor: 2.445

6.  Robust methods to improve efficiency and reduce bias in estimating survival curves in randomized clinical trials.

Authors:  Min Zhang
Journal:  Lifetime Data Anal       Date:  2014-02-13       Impact factor: 1.588

7.  Semiparametric estimation of treatment effect with time-lagged response in the presence of informative censoring.

Authors:  Xiaomin Lu; Anastasios A Tsiatis
Journal:  Lifetime Data Anal       Date:  2011-06-26       Impact factor: 1.588

8.  Covariate adjustment in randomized trials with binary outcomes: targeted maximum likelihood estimation.

Authors:  K L Moore; M J van der Laan
Journal:  Stat Med       Date:  2009-01-15       Impact factor: 2.373

9.  Improving efficiency of inferences in randomized clinical trials using auxiliary covariates.

Authors:  Min Zhang; Anastasios A Tsiatis; Marie Davidian
Journal:  Biometrics       Date:  2008-01-11       Impact factor: 1.701

10.  Variance reduction in randomised trials by inverse probability weighting using the propensity score.

Authors:  Elizabeth J Williamson; Andrew Forbes; Ian R White
Journal:  Stat Med       Date:  2013-09-30       Impact factor: 2.373

View more
  10 in total

Review 1.  Heterogeneity in design and analysis of ICU delirium randomized trials: a systematic review.

Authors:  Elizabeth Colantuoni; Mounica Koneru; Narjes Akhlaghi; Ximin Li; Mohamed D Hashem; Victor D Dinglas; Karin J Neufeld; Michael O Harhay; Dale M Needham
Journal:  Trials       Date:  2021-05-20       Impact factor: 2.279

2.  Correction to: Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards.

Authors:  Iván Díaz; Elizabeth Colantuoni; Daniel F Hanley; Michael Rosenblum
Journal:  Lifetime Data Anal       Date:  2020-01       Impact factor: 1.588

3.  Rejoinder: Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes.

Authors:  David Benkeser; Iván Díaz; Alex Luedtke; Jodi Segal; Daniel Scharfstein; Michael Rosenblum
Journal:  Biometrics       Date:  2021-05-29       Impact factor: 1.701

4.  Improving Precision and Power in Randomized Trials for COVID-19 Treatments Using Covariate Adjustment, for Binary, Ordinal, and Time-to-Event Outcomes.

Authors:  David Benkeser; Iván Díaz; Alex Luedtke; Jodi Segal; Daniel Scharfstein; Michael Rosenblum
Journal:  medRxiv       Date:  2020-06-11

5.  Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes.

Authors:  David Benkeser; Iván Díaz; Alex Luedtke; Jodi Segal; Daniel Scharfstein; Michael Rosenblum
Journal:  Biometrics       Date:  2020-10-11       Impact factor: 1.701

6.  Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection.

Authors:  Shmuel Shoham; Evan M Bloch; Arturo Casadevall; Daniel Hanley; Bryan Lau; Kelly Gebo; Edward Cachay; Seble G Kassaye; James H Paxton; Jonathan Gerber; Adam C Levine; Judith Currier; Bela Patel; Elizabeth S Allen; Shweta Anjan; Lawrence Appel; Sheriza Baksh; Paul W Blair; Anthony Bowen; Patrick Broderick; Christopher A Caputo; Valerie Cluzet; Marie Elena Cordisco; Daniel Cruser; Stephan Ehrhardt; Donald Forthal; Yuriko Fukuta; Amy L Gawad; Thomas Gniadek; Jean Hammel; Moises A Huaman; Douglas A Jabs; Anne Jedlicka; Nicky Karlen; Sabra Klein; Oliver Laeyendecker; Karen Lane; Nichol McBee; Barry Meisenberg; Christian Merlo; Giselle Mosnaim; Han-Sol Park; Andrew Pekosz; Joann Petrini; William Rausch; David M Shade; Janna R Shapiro; J Robinson Singleton; Catherine Sutcliffe; David L Thomas; Anusha Yarava; Martin Zand; Jonathan M Zenilman; Aaron A R Tobian; David Sullivan
Journal:  medRxiv       Date:  2021-12-14

7.  Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma.

Authors:  David J Sullivan; Kelly A Gebo; Shmuel Shoham; Evan M Bloch; Bryan Lau; Aarthi G Shenoy; Giselle S Mosnaim; Thomas J Gniadek; Yuriko Fukuta; Bela Patel; Sonya L Heath; Adam C Levine; Barry R Meisenberg; Emily S Spivak; Shweta Anjan; Moises A Huaman; Janis E Blair; Judith S Currier; James H Paxton; Jonathan M Gerber; Joann R Petrini; Patrick B Broderick; William Rausch; Marie Elena Cordisco; Jean Hammel; Benjamin Greenblatt; Valerie C Cluzet; Daniel Cruser; Kevin Oei; Matthew Abinante; Laura L Hammitt; Catherine G Sutcliffe; Donald N Forthal; Martin S Zand; Edward R Cachay; Jay S Raval; Seble G Kassaye; E Colin Foster; Michael Roth; Christi E Marshall; Anusha Yarava; Karen Lane; Nichol A McBee; Amy L Gawad; Nicky Karlen; Atika Singh; Daniel E Ford; Douglas A Jabs; Lawrence J Appel; David M Shade; Stephan Ehrhardt; Sheriza N Baksh; Oliver Laeyendecker; Andrew Pekosz; Sabra L Klein; Arturo Casadevall; Aaron A R Tobian; Daniel F Hanley
Journal:  medRxiv       Date:  2021-12-21

8.  Optimising precision and power by machine learning in randomised trials with ordinal and time-to-event outcomes with an application to COVID-19.

Authors:  Nicholas Williams; Michael Rosenblum; Iván Díaz
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2022-09-23       Impact factor: 2.175

9.  Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies.

Authors:  Bora Youn; Ira B Wilson; Vincent Mor; Nikolaos A Trikalinos; Issa J Dahabreh
Journal:  Health Serv Res       Date:  2021-03-07       Impact factor: 3.734

10.  Using Mobile Integrated Health and telehealth to support transitions of care among patients with heart failure (MIGHTy-Heart): protocol for a pragmatic randomised controlled trial.

Authors:  Ruth M Masterson Creber; Brock Daniels; Kevin Munjal; Meghan Reading Turchioe; Leah Shafran Topaz; Crispin Goytia; Iván Díaz; Parag Goyal; Mark Weiner; Jiani Yu; Dhruv Khullar; David Slotwiner; Kumudha Ramasubbu; Rainu Kaushal
Journal:  BMJ Open       Date:  2022-03-10       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.